BRAF and central nervous system cancer: We assessed the response to DUSP4 depletion in two BRAF-mutant nonmelanoma cell lines (the glioma line DBTRG and the colorectal carcinoma cell line, LS411N) that were sensitive to MAPK inhibitors (Fig S8).